Herantis Pharma will attend Bio-Europe 2022 and Redeye Neurology Day

On October 5, 2022 Herantis Pharma Plc ("Herantis"), developing disease modifying therapies for Parkinson’s disease, reported that CEO Antti Vuolanto and CSO Henri Huttunen will be attending and holding 1×1 meetings at Bio-Europe 2022 between October 24th–26th, 2022 (Press release, Herantis Pharma, OCT 5, 2022, View Source,c3643277 [SID1234621715]). Additionally, CEO Antti Vuolanto will be attending, presenting, and participating in a CNS panel discussion at Redeyes’ Theme: Neurology Day on October 12th, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Conference Details:

Redeye Theme: Neurology

Bio-Europe 2022

If you are interested in scheduling a 1×1 meeting with Herantis management you can contact the conference organizers, connect with us via the Bio-Europe 1×1 platform, and/or send an email to [email protected].

Use the contact form at the top or bottom of this page to book a free demo to 1stOncology™, an all inclusive cancer drug development intelligence platform from BioSeeker. The platform provides value in oncology for you in areas such as:

Target scouting
Indication selection & expansion
Combinatorial drug settings
Drug repositioning
First in class analysis
Compound cross over analysis
Competitive analysis
Pathway analysis

and much more...

1stOncology is recognized as a
Top 10 Global Pharma Analytic Provider

Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers, signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology!